Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph P Insinga

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
Age-based programs for vaccination against HPVElamin H Elbasha, Erik J Dasbach, Ralph P Insinga, et al.
Journal of General Internal Medicine|July 30, 2005
The incidence of herpes zoster in a United States administrative databaseRalph P Insinga, Robbin F Itzler, James M Pellissier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic EvaluationRalph P Insinga, Erik J Dasbach, Shannon E Allen, et al.
Vaccine|December 7, 2007
Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluationRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2009
Human papillomavirus infections and vulvar disease developmentSuzanne M Garland, Ralph P Insinga, Heather L Sings, et al.
Journal of Medical Economics|September 7, 2018
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the USRalph P Insinga, David J Vanness, Josephine L Feliciano, et al.
Health and Quality of Life Outcomes|June 14, 2012
EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineursMegan R Stafford, Asha Hareendran, Daisy S Ng-Mak, et al.
Current Medical Research and Opinion|January 17, 2019
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the USRalph P Insinga, David J Vanness, Josephine L Feliciano, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|November 8, 2008
The cost-effectiveness of a quadrivalent human papillomavirus vaccine in TaiwanErik J Dasbach, Ralph P Insinga, Yuh Cheng Yang, et al.
Journal of Medical Economics|March 20, 2026
Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparisonDanmeng Huang, Ying Zhang, Riddhi A Babel, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
Age-based programs for vaccination against HPVElamin H Elbasha, Erik J Dasbach, Ralph P Insinga, et al.
Journal of General Internal Medicine|July 30, 2005
The incidence of herpes zoster in a United States administrative databaseRalph P Insinga, Robbin F Itzler, James M Pellissier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic EvaluationRalph P Insinga, Erik J Dasbach, Shannon E Allen, et al.
Vaccine|December 7, 2007
Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluationRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2009
Human papillomavirus infections and vulvar disease developmentSuzanne M Garland, Ralph P Insinga, Heather L Sings, et al.
Journal of Medical Economics|September 7, 2018
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the USRalph P Insinga, David J Vanness, Josephine L Feliciano, et al.
Health and Quality of Life Outcomes|June 14, 2012
EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineursMegan R Stafford, Asha Hareendran, Daisy S Ng-Mak, et al.
Current Medical Research and Opinion|January 17, 2019
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the USRalph P Insinga, David J Vanness, Josephine L Feliciano, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|November 8, 2008
The cost-effectiveness of a quadrivalent human papillomavirus vaccine in TaiwanErik J Dasbach, Ralph P Insinga, Yuh Cheng Yang, et al.
Journal of Medical Economics|March 20, 2026
Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparisonDanmeng Huang, Ying Zhang, Riddhi A Babel, et al.
Pageof 5